Amedisys (AMED) Tops Q2 EPS by 53c, Revs Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amedisys Reports Second Quarter 2020 Financial Results - Reissues 2020 Guidance
July 28, 2020 4:05 PM EDTBATON ROUGE, La., July 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month period ended June 30, 2020.
Three-Month Periods Ended June 30, 2020 and 2019
Net service revenue decreased $8.0Â million to $485.0Â million compared to $493.0Â million in 2019.Net income attributable to Amedisys, Inc. of $34.7Â million compared to $33.7Â million in 2019.Net income attributable to Amedisys, Inc. per diluted share of $1.04 compared to $1.02 in 2019.Adjusted Quarterly Results*
Adjusted EBITDA of $66.4Â million compared to $61.4Â million in 2019.Adjusted net service revenue of $485.0Â million compared to $498.5Â million in... More